Menu

New automated N-glycan profiling web app shaves days off of data interpretations for glycobiologists

The first automated, web-based application that enables routine use of enzymatic digestions to improve N-glycan analyses from New England Biolabs (NEB). This software not only saves precious times for glycobiologists who are more attuned to traditional methods, but also provides the most accurate interpretation of glycan enzymatic digestion data on the market.

Dec 7, 2018
New England BioLabs

The first automated, web-based application that enables routine use of enzymatic digestions to improve N-glycan structural analyses, GlycanAnalyzer, has been released from New England Biolabs (NEB). This software not only saves precious time for glycoanalysts who are more attuned to traditional methods, but also provides the most accurate interpretation of exoglycosidase digestion data on the market. 

N-glycan structure plays a critical role in numerous physiological and pathological processes, making N-glycan structural profiling imperative to biotherapeutic development and quality control. Exoglycosidases can be used to significantly improve the accuracy of N-glycan structure determination using UPLC-FLR-MS analysis. However, interpretation of such analyses, until now, has been performed manually and can take anywhere from several days to several weeks to complete. 

The new GlycanAnalyzer software pattern matches UPLC-FLR-MS peak shifts of released N-glycans following exoglycosidase digestions and automates structure assignments, which no other commercial offerings can do at the moment. It then presents this data visually with links to published reference databases. 

NEB performed a quality test of GlycanAnalyzer using a monoclonal antibody and four glycan standards and found that:

  • 100% of peaks were correctly assigned using the technology, compared to only 81% with the leading competitor

  • Using GlycanAnalyzer’s ‘Assign Top 5’ option (which returns the top 5 peak movements of the sample), all assignments were returned in only 20 minutes

These results indicate that GlycanAnalyzer is not only the most accurate tool of its kind, but it will also shave days off of data interpretation for glycoanalysts in many cases.  Further, the capabilities of GlycanAnalyzer enable facile use of exoglycosidases to improve the quality and accuracy of N-glycan structure profiling.

March 2019

Going Under

Dissecting the effects of anesthetics

Marketplace

Sponsored Product Updates

StemExpress Announces New Distribution Partnerships&nbsp
StemExpress Announces New Distribution Partnerships&nbsp
To continue meeting the needs of clients around the world, StemExpress announces the expansion of its global distribution network to include the Asia Pacific and Australia, adding to their existing networks in North America, Europe, and North Africa.  
Lonza Expands Mycoplasma Detection Portfolio with New Luminometer Designed to Accelerate and Simplify Testing
Lonza Expands Mycoplasma Detection Portfolio with New Luminometer Designed to Accelerate and Simplify Testing
Lonza has further strengthened its extensive mycoplasma detection portfolio with the addition of the Lucetta™ 2 Luminometer, a single-tube system designed to simplify and accelerate mycoplasma detection in cell cultures. Pharmaceutical, biotechnology and academic researchers can now rely on this compact, portable and easy-to-use instrument to run Lonza’s MycoAlert™ Mycoplasma Detection Assays and obtain highly reliable results within just 20 minutes.
FUJIFILM Irvine Scientific Introduces Low Hydrolysate Medium For Insect Cell Expression Systems
FUJIFILM Irvine Scientific Introduces Low Hydrolysate Medium For Insect Cell Expression Systems
FUJIFILM Irvine Scientific, Inc., a world leader in the optimization and manufacture of cell culture media, today announced the introduction of IS Sf Insect medium. The serum-free, animal component-free, low hydrolysate medium is formulated for scalability for the consistent growth and yields of proteins, viral vectors and viral-like particles using baculovirus expression systems (BEVS), in Sf9 and Sf21 cells.
Improving Preclinical Discovery of CRISPR Engineered Immune Cell Therapies
Improving Preclinical Discovery of CRISPR Engineered Immune Cell Therapies
There is an urgent need to characterize the potency and efficacy of CRISPR-Cas9-modified inducible pluripotent stem cell-derived natural killer cells for preclinical cancer immunotherapy research. IsoPlexis' single-cell proteomics system addresses this challenge by connecting each immune cell to cytokine secretion and thereby correlating them to in vivo outcome across a range of disease areas.